{"id":12086,"date":"2024-11-11T15:03:21","date_gmt":"2024-11-11T07:03:21","guid":{"rendered":"https:\/\/flcube.com\/?p=12086"},"modified":"2024-11-11T15:03:23","modified_gmt":"2024-11-11T07:03:23","slug":"pfizer-partners-with-beijing-mabworks-and-kyinno-biotechnology-on-multiple-myeloma-treatments-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=12086","title":{"rendered":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China"},"content":{"rendered":"\n

At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE<\/a>). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer’s first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.<\/p>\n\n\n\n

Focus on Multiple Myeloma Clinical Development<\/strong>
The MoU signifies a strategic move to advance the clinical development of novel therapies for multiple myeloma, a form of blood cancer that affects plasma cells. This partnership aims to leverage the combined expertise and resources of the companies to improve treatment options and outcomes for patients.<\/p>\n\n\n\n

Pfizer Ignite Program Support<\/strong>
Pfizer Ignite, a comprehensive program encompassing preclinical research and development, clinical development, clinical and commercial supply, and production, will play a crucial role in facilitating the collaboration on novel multiple myeloma (MM) product development. The program’s support is expected to accelerate the progress of the partnership’s initiatives.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd,…<\/p>\n","protected":false},"author":1,"featured_media":12089,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2010,1938,863,309],"class_list":["post-12086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-kyinno-biotechnology","tag-mabworks-biotech","tag-nyse-pfe","tag-pfizer"],"yoast_head":"\nPfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer's first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=12086\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=12086\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-11T07:03:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-11T07:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China\",\"datePublished\":\"2024-11-11T07:03:21+00:00\",\"dateModified\":\"2024-11-11T07:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/1730959690786724.jpg\",\"keywords\":[\"Cancer\",\"KYinno Biotechnology\",\"Mabworks Biotech\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12086#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=12086\",\"name\":\"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/1730959690786724.jpg\",\"datePublished\":\"2024-11-11T07:03:21+00:00\",\"dateModified\":\"2024-11-11T07:03:23+00:00\",\"description\":\"At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer's first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=12086\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/1730959690786724.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/1730959690786724.jpg\",\"width\":800,\"height\":533,\"caption\":\"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=12086#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China - Insight, China's Pharmaceutical Industry","description":"At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer's first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=12086","og_locale":"en_US","og_type":"article","og_title":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=12086","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-11T07:03:21+00:00","article_modified_time":"2024-11-11T07:03:23+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=12086#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=12086"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China","datePublished":"2024-11-11T07:03:21+00:00","dateModified":"2024-11-11T07:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=12086"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=12086#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","keywords":["Cancer","KYinno Biotechnology","Mabworks Biotech","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=12086#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=12086","url":"https:\/\/flcube.com\/?p=12086","name":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=12086#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=12086#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","datePublished":"2024-11-11T07:03:21+00:00","dateModified":"2024-11-11T07:03:23+00:00","description":"At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd, and KYinno Biotechnology Co., Ltd, have jointly announced a cooperation Memorandum of Understanding (MoU) with global pharmaceutical leader Pfizer (NYSE: PFE). The collaboration focuses on the clinical development of innovative treatment solutions for patients with multiple myeloma, marking Pfizer's first partnership with domestic biotechs in mainland China since the implementation of its Ignite plan in the country.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=12086#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=12086"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=12086#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","width":800,"height":533,"caption":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=12086#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/1730959690786724.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12086"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12086\/revisions"}],"predecessor-version":[{"id":12090,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/12086\/revisions\/12090"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/12089"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}